Special problems with antiarrhythmic drugs in the elderly: Safety, tolerability, and efficacy

American Journal of Geriatric Cardiology

Volumn 11, Issue 6, 2002, Pages

  Dayer, Mark ^a   Hardman, Suzanna M C ^a  

^a St Mary's Wing   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DOFETILIDE; FLECAINIDE; IBUTILIDE; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL;

AGE; AGING; CARDIOVASCULAR RISK; CARDIOVERSION; COMORBIDITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; LUNG TOXICITY; PATIENT CARE; REVIEW; SINUS RHYTHM; TORSADE DES POINTES;

EID: 0036850092     PISSN: 10767460     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1076-7460.2002.0069.x     Document Type: Review

References (58)

1. Hohnloser SH, Kuck K, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PLAF): A randomised trial. Lancet. 2000;356:1789-1794.
2. Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92:1954-1968.
3. David D, Sengi ED, Klein HO, et al. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: Beneficial effect of an added beta-adrenergic blocking agent. Am J Cardiol. 1979;44:1378-1382.
4. Hardman SMC, Biggs T, Noble MIM, et al. Evidence for an influence of mechanical restitution during chronic atrial fibrillation in patients. Cardiovasc Res. 1998;38:82-90.
5. Hardman SMC, Noble MIM, Seed WA. Post-extrasystolic potentiation and its contribution to the beat to beat variation of the pulse during atrial fibrillation. Circulation. 1992;86:1223-1232.
6. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration and ventricular rate of paroxysmal atrial fibrillation: The effect of digoxin. Br Heart J. 1990;63:225-227.
7. Falk RH, Knowlton AA, Bernard SA, et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Intern Med. 1987;106:503-506.
8. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. Eur Heart J. 1997;18:649-654.
9. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:5255-5233.
10. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 1989;63:925-929.
11. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol. 2001;38:1231-1265.
12. DiBianco R, Morganroth J, Freitag JA, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J. 1984;108:1121-1127.
13. Atwood JE, Myers J, Quaglietti S, et al. Effect of betaxolol on the hemodynamic, gas exchange, and cardiac output response to exercise in chronic atrial fibrillation. Chest. 1999;115:1175-1180.
14. Wong CK, Lau CP, Leung WH, et al. Usefulness of labetalol in chronic atrial fibrillation. Am J Cardiol. 1990;66:1212-1215.
15. Atwood JE, Sullivan M, Forbes S, et al. Effect of betaadrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol. 1987;10:314-320.
16. Hardman SMC. Ventricular function in atrial fibrillation. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation: Mechanicians and Management. 2nd Ed. Philadelphia, PA: Lippincott-Raven; 1997:91-108.
17. Heywood JT. Calcium channel blockers for heart rate control in atrial fibrillation complicated by congestive heart failure. Can J Cardiol. 1995;11:823-826.
18. De Simone A, Stabile G, Vitale DF, et al. Pre-treatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol. 1999;34:810-814.
19. Akiyama T, Pawitan Y, Campbell WB, et al. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators. J Am Ger Soc. 1992;40:666-672.
20. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol. 1992;20:527-532.
21. Akiyama T, Pawitan Y, Greenberg H, et al. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol. 1991;68:1551-1555.
22. Nakazawa H, Lythall DA, Noh J, et al. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J. 2000;21:327-333.
23. Kerin NZ, Faitel K, Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs. quinidine for conversion of atrial fibrillation. Arch Intern Med. 1996;156:49-53.
24. Naccarelli GV, Dorian P, Hohnloser SH, et al. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol. 1996;77:53A-59A.
25. Sodermark T, Jonsson B, Olsson A, et al. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm. Br Heart J. 1975:37:486-492.
26. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990;82:1106-1116.
27. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation study: Final results. Circulation. 1991;84:527-539.
28. Fresco C, Proclemer A, Pavan A, et al. Intravenous propafenone in paroxysmal atrial fibrillation: A randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. Clin Cardiol. 1996:19:409-412.
29. Boriani G, Biffi M, Capucci A, et al. Oral loading with propafenone: A placebo-controlled study in elderly and non-elderly patients with recent onset atrial fibrillation. Pace. 1998;21:2465-2469.
30. Bellandi F, Dabizzi RP, Cantini F, et al. Intravenous propafenone: Efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation - A single-blind placebo-controlled study. Cardiovasc Drug Ther. 1996;10:153-157.
31. Bellandi F, Cantini F, Pedone T, et al. Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: A placebo-controlled study. Clin Cardiol. 1995;18:631-634.
32. Azpitarte J, Alvarez M, Baun O et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J. 1997;18:1649-1654.
33. Botto GL, Capucci A, Bonini W, et al. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: Comparison of tow regimens. Int J Cardiol. 1997;58:55-61.
34. Pietersen AH, Hellemann H. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Am J Cardiol. 1991;67:713-717.
35. Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation. 1989;80:1557-1570.
36. UK Propafenone PSVT Study Group. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation. 1995;92:2550-2557.
37. Singh SN, Fletcher RD, Fisher SG. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. New Engl J Med. 1995;333:77-82.
38. Cotter G, Blatt A, Kaluski E, et al. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: The effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study. Eur Heart J. 1999;20:1833-1842.
39. Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol. 1996;27:1079-1082.
40. Cowan JC, Gardiner P, Reid DS, et al. A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected acute myocardial infarction. J Cardiovasc Pharm. 1986;8:252-256.
41. Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J. 1995;16:521-528.
42. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998;98:2574-2579.
43. Kochiadakis GE, Igoumenidis NE, Solomou MC, et al. Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am J Cardiol. 1999;83:58-61.
44. Capucci A, Villani GQ, Aschieri D, et al. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J. 2000;21:66-73.
45. Kochiadakis GE, Igoumenidis NE, Marketou ME, et al. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: A comparative, placebo controlled study. Heart. 2000;84:251-257.
46. Kochiadakis GE, Igoumenidis NE, Marketou ME, et al. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1998;81:995-998.
47. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 1990;82:1932-1939.
48. Benditt DG, Williams JH, Jin J, et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1999;84:270-277.
49. Reimold SC, Cantillon CO, Friedman PL, et al. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1993;71:558-563.
50. Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med. 1999;340:1849-1854.
51. Abi-Mansour P, Carberry PA, McCowan RJ, et al. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Am Heart J. 1998;136:632-642.
52. Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigation. Circulation. 1996;94:1613-1621.
53. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study. J Am Coll Cardiol. 1996;28:130-136.
54. Volgman AS, Carberry PA, Stambler BS, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 1998;31:1414-1419.
55. Norgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J. 1999;137:1062-1069.
56. Bianconi L, Castro A, Dinelli M, et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J. 2000;21:1265-1273.
57. Falk RH, Pollak A, Singh SN, et al. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol. 1997;29:385-390.
58. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality, Dofetilide Study Group. N Engl J Med. 1999;341:857-865.